Cited by 185Protein Kinase Regulation and GTPase SignalingPI3K/AKT/mTOR signaling in cancerSignaling Pathways in Disease

The DOI matches its Crossref record; 108 of the 109 references it cites were found in a registry or an index.

Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

Kortmansky, Jeremy, Schwartz, Gary K.·2003·Cancer Investigation

DOI 10.1081/cnv-120025095

Open this paper in CoChat — free account

Abstract

Modulation of PKC represents a novel approach to cancer therapy. Bryostatin-1 is a macrocyclic lactone derived from a marine invertebrate that binds to the regulatory domain of protein kinase C. Short-term exposure to bryostatin-1 promotes activation of PKC, whereas prolonged exposure promotes significant downregulation of PKC. In numerous hematological and solid tumor cell lines, bryostatin-1 inhibits proliferation, induces differentiation, and promotes apoptosis. Furthermore, preclinical studies indicate that bryostatin-1 potently enhances the effect of chemotherapy. In many cases, this effect is sequence specific. Bryostatin-1 is currently in phase I and phase II clinical trials. The major toxicities are myalgias, nausea, and vomiting. Although there is minimal single-agent activity, combinations with standard chemotherapy are providing very encouraging results and indicate a new direction in cancer therapy.

Integrity signals

Registry

Crossref · 10.1081/cnv-120025095

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The extended protein kinase C superfamily
MELLOR, H., & Parker, P. J. (1998) · Biochemical Journal · doi:10.1042/bj3320281 · Cited by 1,539
Matrix metalloproteinase inhibitors
Wojtowicz‐Praga, S., Dickson, R. B., & Hawkins, M. (1997) · Investigational New Drugs · doi:10.1023/a:1005722729132 · Cited by 524
Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma
Moch, H., Gasser, T., Amin, M. B., Torhorst, J. K. H., Sauter, G., & Mihatsch, M. J. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3 · Cited by 472
A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis
Ruvolo, P. P., Deng, X., Carr, B. K., & May, W. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25436 · Cited by 452
Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.
Kraft, A. S., Smith, J. B., & Berkow, R. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.5.1334 · Cited by 257
Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells.
Hocevar, B. A., & Fields, A. P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52396-6 · Cited by 248
Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin
Hennings, H., Blumberg, P. M., Pettit, G. R., Herald, C. L., Shores, R., & Yuspa, S. H. (1987) · Carcinogenesis · doi:10.1093/carcin/8.9.1343 · Cited by 230
Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis.
May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatsha, K. A., & Davidson, N. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47099-8 · Cited by 219
Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.
Wender, P. A., CRIBBS, C. M., Koehler, K. F., Sharkey, N. A., Herald, C. L., Kamano, Y., Pettit, G. R., & Blumberg, P. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7197 · Cited by 201
Bryostatin and CD40‐ligand enhance apoptosis resistance and induce expression of cell survival genes in B‐cell chronic lymphocytic leukaemia
Kitada, S., Zapata, J. M., Andreeff, M., & Reed, J. C. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01642.x · Cited by 187

Show all 109 references

Research works printed but not linked: 43

Hu Z. B., 1993, Leukemia, 7, 1817
Lilly M., 1990, Cancer Res., 50, 5520
al-Katib A., 1993, Exp. Hematol., 21, 61
Kraft A. S., 1987, Oncogene, 1, 111
Drexler H. G., 1989, Blood, 74, 1747, 10.1182/blood.V74.5.1747.1747 · DOI
Wall N. R., 2000, Int. J. Mol. Med., 5, 165
Wang H., 1998, Int. J. Mol. Med., 1, 915
Gschwend J. E., 2000, Mol. Pharmacol., 57, 1224
Asiedu C., 1995, Cancer Res., 55, 3716
Koutcher J. A., 2000, Clin. Cancer Res., 6, 1498
Al-Katib A. M., 1998, Clin. Cancer Res., 4, 1305
Scala S., 1995, Clin. Cancer Res., 1, 1581
Lilly M., 1991, Leukemia, 5, 283
Berkow R. L., 1993, Cancer Res., 53, 2810
Szallasi Z., 1996, Cancer Res., 56, 2105
Schuchter L. M., 1991, Cancer Res., 51, 682
Hornung R. L., 1992, Cancer Res., 52, 101
Kennedy M. J., 1992, Cancer Res., 52, 1278
10.1097/00008390-200004000-00001 · DOI
McBain J. A., 1990, Cell Growth Differ., 1, 281
Jones R. J., 1990, Blood, 75, 1319, 10.1182/blood.V75.6.1319.1319 · DOI
Mohammad R. M., 1994, Cancer Res., 54, 165
Mohammad R. M., 1998, Clin. Cancer Res., 4, 1337
Mohammad R. M., 2000, Clin. Cancer Res., 6, 4950
Beck F. W., 2000, Int. J. Mol. Med., 5, 341
Mohammad R. M., 1999, Int. J. Oncol., 14, 945
Kaubisch A. K.D., 2000, Proc. Am. Soc. Clin. Oncol., 19, 230a
Marshall J. I.J.M., 1998, Proc. Am. Assoc. Cancer Res., 39, 601
Langevin A. M.B.M., 1998, Proc. Am. Soc. Clin. Oncol., 17, 206
Weitman S., 1999, Clin. Cancer Res., 5, 2344
Institute N. C, 1997, Fact Sheet
Grant S., 1998, Clin. Cancer Res., 4, 611
Pavlick A. C.H.A., 2001, Proc. Am. Soc. Clin. Oncol., 20, a328
Bangalore N. S.B.S., 2000, Proc. Am. Soc. Clin. Oncol., 19
Lenz H. J.G.M., 2000, Proc. Am. Soc. Clin. Oncol., 19
Dowlati A. R.K., 2000, Proc. Am. Soc. Clin. Oncol., 19
Grant S. C.L., 2000, Blood, 93, a590
Zonder J. A., 2001, Clin. Cancer Res., 7, 38
Varterasian M. L., 2000, Clin. Cancer Res., 6, 825
Ilson D. S.M., 2001, Proc. Am. Soc. Clin. Oncol., 20, a633,159
Charoentum C. M.A., 2001, Proc. Am. Soc. Clin. Oncol., 20, a2834
Tuttle T. M., 1992, Cancer Res., 52, 548
Tuttle T. M., 1993, Cancer Res., 53, 833

Sorted by citations

Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
PKC Regulates a Farnesyl-Electrostatic Switch on K-Ras that Promotes its Association with Bcl-Xl on Mitochondria and Induces Apoptosis
Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L. P., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467
Tetrahydrofuran-Containing Macrolides: A Fascinating Gift from the Deep Sea
Lorente, A., Lamariano‐Merketegi, J., Alberício, F., & Álvarez, M. (2013) · Chemical Reviews · doi:10.1021/cr3004778 · Cited by 354
Recent advances in deep-sea natural products
Skropeta, D., & Wei, L. (2014) · Natural Product Reports · doi:10.1039/c3np70118b · Cited by 238
An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs
Ruiz-Torres, V., Encinar, J. A., Herranz‐López, M., Pérez-Sánchez, A., Galiano, V., Barrajón‐Catalán, E., & Micol, V. (2017) · Molecules · doi:10.3390/molecules22071037 · Cited by 234
Protein kinase C pharmacology: refining the toolbox
Wu-Zhang, A. X., & Newton, A. C. (2013) · Biochemical Journal · doi:10.1042/bj20130220 · Cited by 200
Deep-sea natural products
Skropeta, D. (2008) · Natural Product Reports · doi:10.1039/b808743a · Cited by 196
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro
DeChristopher, B. A., Loy, B. A., Marsden, M. D., Schrier, A. J., Zack, J. A., & Wender, P. A. (2012) · Nature Chemistry · doi:10.1038/nchem.1395 · Cited by 163
Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis
Crane, E. A., & Gademann, K. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201505863 · Cited by 160
Marine Antitumor Drugs: Status, Shortfalls and Strategies
Bhatnagar, I., & Kim, S. (2010) · Marine Drugs · doi:10.3390/md8102702 · Cited by 154
Unexpected applications of secondary metabolites
Vaishnav, P., & Demain, A. L. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.11.006 · Cited by 154
Total Synthesis of Bryostatin 7 via C–C Bond-Forming Hydrogenation
Lu, Y., Woo, S. K., & Krische, M. J. (2011) · Journal of the American Chemical Society · doi:10.1021/ja205673e · Cited by 148
Efficient Synthetic Access to a New Family of Highly Potent Bryostatin Analogues via a Prins-Driven Macrocyclization Strategy
Wender, P. A., DeChristopher, B. A., & Schrier, A. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8015632 · Cited by 132
Neuronal ELAV proteins enhance mRNA stability by a PKCα-dependent pathway
Pascale, A., Amadio, M., Scapagnini, G., Lanni, C., Racchi, M., Provenzani, A., Govoni, S., Alkon, D. L., & Quattrone, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504702102 · Cited by 129
Exploring the potential of marine natural products in drug development: A comprehensive review
Banday, A. H., Azha, N. U., Farooq, R., Sheikh, S. A., Ganie, M. A., Parray, M. N., Mushtaq, H., Hameed, I., & Lone, M. A. (2024) · Phytochemistry Letters · doi:10.1016/j.phytol.2024.01.001 · Cited by 136
Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
Kawano, T., Inokuchi, J., Eto, M., Murata, M., & Kang, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111748 · Cited by 120
Comprehensive Structure–Activity Relationship Studies of Macrocyclic Natural Products Enabled by Their Total Syntheses
Itoh, H., & Inoue, M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00063 · Cited by 119
Total Synthesis of Bryostatin 9
Wender, P. A., & Schrier, A. J. (2011) · Journal of the American Chemical Society · doi:10.1021/ja203034k · Cited by 118
New Approaches to the Total Synthesis of the Bryostatin Antitumor Macrolides
Hale, K. J., & Manaviazar, S. (2010) · Chemistry - An Asian Journal · doi:10.1002/asia.200900634 · Cited by 115
CRISPR-mediated Activation of Latent HIV-1 Expression
Limsirichai, P., Gaj, T., & Schaffer, D. V. (2015) · Molecular Therapy · doi:10.1038/mt.2015.213 · Cited by 112
Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV
Wender, P. A., Hardman, C., Ho, S., Jeffreys, M. S., Maclaren, J. K., Quiroz, R. V., Ryckbosch, S. M., Shimizu, A., Sloane, J. L., & Stevens, M. C. (2017) · Science · doi:10.1126/science.aan7969 · Cited by 112
Targeting apoptosis pathways by natural compounds in cancer: Marine compounds as lead structures and chemical tools for cancer therapy
von Schwarzenberg, K., & Vollmar, A. M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.07.004 · Cited by 104
Trading molecules and tracking targets in symbiotic interactions
Schmidt, E. W. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.101 · Cited by 101
Protein kinase C intervention—the state of play
Roffey, J., Rossé, C., Linch, M. D., Hibbert, A. P., McDonald, N. Q., & Parker, P. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.019 · Cited by 100
Enzyme Inhibitors from Marine Invertebrates
Nakao, Y., & Fusetani, N. (2007) · Journal of Natural Products · doi:10.1021/np060600x · Cited by 90
Wealth of Opportunity - The C1 Domain as a Target for Drug Development
Blumberg, P. M., Kedei, N., Lewin, N. E., Yang, D., Czifra, G., Pu, Y., Peach, M. L., & Márquez, V. E. (2008) · Current Drug Targets · doi:10.2174/138945008785132376 · Cited by 82
Anticancer Agents from Diverse Natural Sources
Khazir, J., Riley, D. L., Pilcher, L. A., De-Maayer, P., & Mir, B. A. (2014) · Natural Product Communications · doi:10.1177/1934578x1400901130 · Cited by 81
Upregulation of Osteopontin by Osteocytes Deprived of Mechanical Loading or Oxygen
Gross, T. S., King, K. A., Rabaia, N. A., Pathare, P. P., & Srinivasan, S. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041004 · Cited by 82
Apoptosis inducing lead compounds isolated from marine organisms of potential relevance in cancer treatment
Beesoo, R., Neergheen, V. S., Bhagooli, R., & Bahorun, T. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.03.005 · Cited by 78
Prins Cyclization of Bis(silyl) Homoallylic Alcohols to Form 2,6‐cis‐Tetrahydropyrans Containing a Geometrically Defined Exocyclic Vinylsilane: Efficient Synthesis of Ring B of the Bryostatins
Lu, J., Song, Z., Zhang, Y., Gan, Z., & Li, H. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201323 · Cited by 74
The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 73
Kinase Inhibitors from Marine Sponges
Skropeta, D., Pastro, N. J., & Zivanovic, A. (2011) · Marine Drugs · doi:10.3390/md9102131 · Cited by 72
Protein kinase D1: a protein of emerging translational interest
Jaggi, M. (2007) · Frontiers in bioscience · doi:10.2741/2349 · Cited by 66
The Phylum Bryozoa as a Promising Source of Anticancer Drugs
Figuerola, B., & Àvila, C. (2019) · Marine Drugs · doi:10.3390/md17080477 · Cited by 67
Conformation–activity relationships of polyketide natural products
Larsen, E. M., Wilson, M. R., & Taylor, R. E. (2015) · Natural Product Reports · doi:10.1039/c5np00014a · Cited by 58
Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Raghuvanshi, R., & Bharate, S. B. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200325110444 · Cited by 56
The Design, Synthesis, and Evaluation of C7 Diversified Bryostatin Analogs Reveals a Hot Spot for PKC Affinity
Wender, P. A., & Verma, V. A. (2008) · Organic Letters · doi:10.1021/ol801235h · Cited by 54
Total Synthesis of Bryostatin 8 Using an Organosilane‐Based Strategy
Zhang, Y., Guo, Q., Sun, X., Lu, J., Cao, Y., Pu, Q., Chu, Z., Gao, L., & Song, Z. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201711452 · Cited by 53
Concise Synthesis of the Bryostatin A-Ring via Consecutive C−C Bond Forming Transfer Hydrogenations
Lu, Y., & Krische, M. J. (2009) · Organic Letters · doi:10.1021/ol901096d · Cited by 53
PKC activator therapeutic for mild traumatic brain injury in mice
Zohar, O., Lavy, R., Zi, X., Nelson, T. J., Hongpaisan, J., Pick, C. G., & Alkon, D. L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.001 · Cited by 53
Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy
Hardman, C., Ho, S., Shimizu, A., Luu-Nguyen, Q. H., Sloane, J. L., Soliman, M. S. A., Marsden, M. D., Zack, J. A., & Wender, P. A. (2020) · Nature Communications · doi:10.1038/s41467-020-15742-7 · Cited by 49
Natural product mode of action (MOA) studies: a link between natural and synthetic worlds
Clair, J. J. L. (2010) · Natural Product Reports · doi:10.1039/b909989c · Cited by 48
Translating Nature’s Library: The Bryostatins and Function‐Oriented Synthesis
Wender, P. A., Loy, B. A., & Schrier, A. J. (2011) · Israel Journal of Chemistry · doi:10.1002/ijch.201100020 · Cited by 48
Bioactive Compounds from Marine Heterobranchs
Àvila, C., & Angulo‐Preckler, C. (2020) · Marine Drugs · doi:10.3390/md18120657 · Cited by 48
Identification, Characterization and Initial Hit-to-Lead Optimization of a Series of 4-Arylamino-3-Pyridinecarbonitrile as Protein Kinase C theta (PKCθ) Inhibitors
Cole, D. C., Asselin, M., Brennan, A., Czerwiński, R., Ellingboe, J. W., Fitz, L. J., Greco, R., Huang, X., Joseph‐McCarthy, D., Kelly, M. F., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800214a · Cited by 46
Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds
Dayanidhi, D. L., Thomas, B. C., Osterberg, J. S., Vuong, M., Vargas, G., Kwartler, S. K., Schmaltz, E., Dunphy‐Daly, M. M., Schultz, T. F., Rittschof, D., et al. (2021) · Frontiers in Marine Science · doi:10.3389/fmars.2020.614766 · Cited by 48
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC- II depletion
Biberacher, V., Decker, T. W., Oelsner, M., Wagner, M. M., Bogner, C., Schmidt, B., Kreitman, R. J., Peschel, C., Pastan, I. H., Büschenfelde, C. M. Z., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.049155 · Cited by 45
Protein Kinase Cϵ (PKCϵ) Promotes Synaptogenesis through Membrane Accumulation of the Postsynaptic Density Protein PSD-95
Sen, A., Hongpaisan, J., Wang, D., Nelson, T. J., & Alkon, D. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.730440 · Cited by 46
Bryostatin Enhancement of Memory inHermissenda
Kuzirian, A. M., Epstein, H. T., Gagliardi, C., Nelson, T. J., Sakakibara, M., Taylor, C., Scioletti, A. B., & Alkon, D. L. (2006) · Biological Bulletin · doi:10.2307/4134558 · Cited by 43
Total Synthesis and Initial Biological Evaluation of New B-Ring-Modified Bryostatin Analogs
Wender, P. A., Horan, J. C., & Verma, V. A. (2006) · Organic Letters · doi:10.1021/ol0620904 · Cited by 42
Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma
Lam, A. P., Sparano, J. A., Vinciguerra, V. P., Ocean, A. J., Christos, P. J., Höchster, H. S., Camacho, F., Goel, S., Mani, S., & Kaubisch, A. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181a31920 · Cited by 41
The Medicinal Potential of Promising Marine Macrolides with Anticancer Activity
Qi, Y., & Ma, S. (2011) · ChemMedChem · doi:10.1002/cmdc.201000534 · Cited by 41
Marine Macrolides, a Promising Source of Antitumor Compounds
Napolitano, J. G., Daranas, A. H., Norte, M., & Fernández, J. J. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009787313800 · Cited by 40
Enhancement of Cisplatin Sensitivity of Cisplatin-Resistant Human Cervical Carcinoma Cells by Bryostatin 1
Mohanty, S., Huang, J., & Basu, A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0450 · Cited by 40
Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma
Roberts, J. D., Smith, M. R., Feldman, E. J., Cragg, L., Millenson, M. M., Roboz, G. J., Honeycutt, C., Thune, R., Padavic‐Shaller, K., Carter, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2730 · Cited by 39
Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C–C Bond Formation: Potency Does Not Confer Bryostatin-like Biology
Ketcham, J. M., Volchkov, I., Chen, T., Blumberg, P. M., Kedei, N., Lewin, N. E., & Krische, M. J. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08695 · Cited by 37
Bryostatin-1: a promising compound for neurological disorders
Tian, Z., Lu, X.-T., Jiang, X., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1187411 · Cited by 36
Bryostatin-1, a Naturally Occurring Antineoplastic Agent, Acts as a Toll-like Receptor 4 (TLR-4) Ligand and Induces Unique Cytokines and Chemokines in Dendritic Cells
Ariza, M. E., Ramakrishnan, R., Singh, N. P., Chauhan, A., Nagarkatti, P. S., & Nagarkatti, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135921 · Cited by 36
Bryostatin 1 modulates β-catenin subcellular localization and transcription activity through protein kinase D1 activation
Jaggi, M., Chauhan, S. C., Du, C., & Balaji, K. C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0119 · Cited by 36
Synthesis of seco -B-Ring Bryostatin Analogue WN-1 via C–C Bond-Forming Hydrogenation: Critical Contribution of the B-Ring in Determining Bryostatin-like and Phorbol 12-Myristate 13-Acetate-like Properties
Andrews, I. P., Ketcham, J. M., Blumberg, P. M., Kedei, N., Lewin, N. E., Peach, M. L., & Krische, M. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja507825s · Cited by 35
“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced LymphomaIn Vivo
DeChristopher, B. A., Fan, A. C., Felsher, D. W., & Wender, P. A. (2012) · Oncotarget · doi:10.18632/oncotarget.438 · Cited by 35
Inhibitors of signal transduction protein kinases as targets for cancer therapy
Mikalsen, T., Gerits, N., & Moens, U. L. (2006) · Biotechnology annual review · doi:10.1016/s1387-2656(06)12006-2 · Cited by 36
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm
Schwartz, L. H., Colville, J., Ginsberg, M. S., Wang, L., Mazumdar, M., Kalaigian, J., Hricak, H., Ilson, D. H., & Schwartz, G. K. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl058 · Cited by 34
Self-citation
Computer-Guided Design, Synthesis, and Protein Kinase C Affinity of a New Salicylate-Based Class of Bryostatin Analogs
Wender, P. A., Nakagawa, Y., Near, K. E., & Staveness, D. (2014) · Organic Letters · doi:10.1021/ol502491f · Cited by 32
Natural Marine Products: Anti-Colorectal Cancer In Vitro and In Vivo
Han, N., Li, J., & Li, X. (2022) · Marine Drugs · doi:10.3390/md20060349 · Cited by 32
Synthesis and PKC Binding of a New Class of A-Ring Diversifiable Bryostatin Analogues Utilizing a Double Asymmetric Hydrogenation and Cross-Coupling Strategy
Wender, P. A., & Horan, J. C. (2006) · Organic Letters · doi:10.1021/ol0618149 · Cited by 32
Protein Kinase C
El‐Rayes, B. F., Ali, S. S., Philip, P. A., & Sarkar, F. H. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815ceaf7 · Cited by 31
From the Sea to Anticancer Therapy
Russo, P., Nastrucci, C., & Cesario, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796642652 · Cited by 31
Characterization and engineering of the biosynthesis gene cluster for antitumor macrolides PM100117 and PM100118 from a marine actinobacteria: generation of a novel improved derivative
García‐Salcedo, R., Olano, C., Gómez, C., Fernández, R., Braña, A. F., Méndez, C., de la Calle, F., & Salas, J. A. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0443-5 · Cited by 29
Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
Shetu, S. A., & Bandyopadhyay, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073706 · Cited by 31
Biology, pathology, and therapeutic targeting of RAS
Rhett, J. M., Khan, I., & O’Bryan, J. P. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.002 · Cited by 29
C1 Domain-Targeted Isophthalate Derivatives Induce Cell Elongation and Cell Cycle Arrest in HeLa Cells
Talman, V., Tuominen, R. K., af Gennäs, G. B., Yli‐Kauhaluoma, J. T., & Ekokoski, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020053 · Cited by 28
A High-Throughput Cell-Based Assay to Identify Specific Inhibitors of Transcription Factor AP-1
Ruocco, K. M., Goncharova, E. I., Young, M. R., Colburn, N. H., McMahon, J. B., & Henrich, C. J. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106296686 · Cited by 27
Toward a Biorelevant Structure of Protein Kinase C Bound Modulators: Design, Synthesis, and Evaluation of Labeled Bryostatin Analogues for Analysis with Rotational Echo Double Resonance NMR Spectroscopy
Loy, B. A., Lesser, A. B., Staveness, D., Billingsley, K. L., Cegelski, L., & Wender, P. A. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b00886 · Cited by 26
Targeting PKC in microglia to promote remyelination and repair in the CNS
Kim, P. M., & Kornberg, M. D. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.008 · Cited by 25
Some Phorbol Esters Might Partially Resemble Bryostatin 1 in their Actions on LNCaP Prostate Cancer Cells and U937 Leukemia Cells
Kedei, N., Lubart, E. S., Lewin, N. E., Telek, A., Lim, L., Mannan, P., Garfield, S. H., Kraft, M. B., Keck, G. E., Kolusheva, S., et al. (2011) · ChemBioChem · doi:10.1002/cbic.201100064 · Cited by 25
Inhibition of Inflammation, Suppression of Matrix Metalloproteinases, Induction of Neurogenesis, and Antioxidant Property Make Bryostatin-1 a Therapeutic Choice for Multiple Sclerosis
Safaeinejad, F., Bahrami, S., Redl, H. R., & Niknejad, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00625 · Cited by 24
Phase I Study of Bryostatin 1 and Gemcitabine
El-Rayes, B. F., Gadgeel, S. M., Shields, A. F., Manza, S. G., LoRusso, P. M., & Philip, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1419 · Cited by 24
Achyranthes aspera L. leaf extract induced anticancer effects on Dalton's Lymphoma via regulation of PKCα signaling pathway and mitochondrial apoptosis
Singh, R. K., Verma, P. K., Kumar, A., Kumar, S., & Acharya, A. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114060 · Cited by 23
Role of the A-Ring of Bryostatin Analogues in PKC Binding: Synthesis and Initial Biological Evaluation of New A-Ring-Modified Bryologs
Wender, P. A., Clarke, M. O., & Horan, J. C. (2005) · Organic Letters · doi:10.1021/ol0504650 · Cited by 23
Advanced Technologies for Large Scale Supply of Marine Drugs
Martínez, H., Santos, M., Pedraza, L., & Testera, A. M. (2025) · Marine Drugs · doi:10.3390/md23020069 · Cited by 22
Improved Protein Kinase C Affinity through Final Step Diversification of a Simplified Salicylate-Derived Bryostatin Analog Scaffold
Wender, P. A., & Staveness, D. (2014) · Organic Letters · doi:10.1021/ol502492b · Cited by 22
Phosphorylation controls a dual-function polybasic nuclear localization sequence in the adapter protein SH2B1β to regulate its cellular function and distribution
Maures, T. J., Su, H.-W., Argetsinger, L. S., Grinstein, S., & Carter‐Su, C. (2011) · Journal of Cell Science · doi:10.1242/jcs.078949 · Cited by 23
Genetic variants of the peroxisome proliferator‐activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer
Liu, X., Qian, D., Liu, H., Abbruzzese, J. L., Luo, S., Walsh, K. M., & Wei, Q. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23208 · Cited by 21
PKCη as a therapeutic target in glioblastoma multiforme
Martin, P. M., & Hussaini, I. M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.299 · Cited by 21
Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells
Hammond, C., Shi, Y., Mena, J., Tomic, J., Cervi, D. N., He, L., Millar, A. E., Debenedette, M. A., Schuh, A. C., Baryza, J. L., et al. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200501000-00004 · Cited by 21
Synthetisch gewonnene Naturstofffragmente in der Wirkstoffentwicklung
Crane, E. A., & Gademann, K. (2016) · Angewandte Chemie · doi:10.1002/ange.201505863 · Cited by 20
Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death
Staveness, D., Abdelnabi, R., Schrier, A. J., Loy, B. A., Verma, V. A., DeChristopher, B. A., Near, K. E., Neyts, J. H., Delang, L., Leyssen, P., et al. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01016 · Cited by 20
Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action
Kedei, N., Telek, A., Michalowski, A. M., Kraft, M. B., Li, W., Poudel, Y. B., Rudra, A., Petersen, M. E., Keck, G. E., & Blumberg, P. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.028 · Cited by 20
Protein kinase C inhibitors: a patent review (2008 – 2009)
Sobhia, M. E., Grewal, B. K., Paul, S., Patel, J. A., Kaur, A., Haokip, T., & Kokkula, A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.805205 · Cited by 19
Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives
Tisi, R., Gaponenko, V., Vanoni, M., & Sacco, E. (2020) · Biomolecules · doi:10.3390/biom10111535 · Cited by 18
Overexpression of PKCε sensitizes LNCaP human prostate cancer cells to induction of apoptosis by bryostatin 1
Powell, C. T., & Yin, L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21511 · Cited by 18
Marine Natural Products in Inflammation‐Related Diseases: Opportunities and Challenges
Zhang, T., Ouyang, Z., Zhang, Y., Sun, H., Kong, L., Xu, Q., Qu, J., & Sun, Y. (2025) · Medicinal Research Reviews · doi:10.1002/med.22109 · Cited by 19
Identification of protein kinase C isozymes involved in the anti-proliferative and pro-apoptotic activities of 10-Methyl-aplog-1, a simplified analog of debromoaplysiatoxin, in several cancer cell lines
Hanaki, Y., Shikata, Y., Kikumori, M., Hotta, N., Imoto, M., & Irie, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.052 · Cited by 17
Rethinking the Role of Natural Products: Function‐Oriented Synthesis, Bryostatin, and Bryologs
Wender, P. A., Donnelly, A. C., Loy, B. A., Near, K. E., & Staveness, D. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527676545.ch14 · Cited by 17
Marine-derived secondary metabolites in oncology: A comprehensive review
Abuzahrah, S. S., Elbehairi, S. E. I., Bakhsh, T., Atwa, A., Juaid, N., & Mekky, R. H. (2025) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2025.100300 · Cited by 18
Discovery of a novel protein kinase C activator from Croton tiglium for inhibition of non-small cell lung cancer
Wang, Y., Tang, C., Yao, S., Lai, H., Li, R., Xu, J., Wang, Q., Fan, X., Wu, Q., Leung, E. L., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153100 · Cited by 16
Prins Cyclization of Bis(silyl) Homoallylic Alcohols to Form 2,6‐cis‐Tetrahydropyrans Containing a Geometrically Defined Exocyclic Vinylsilane: Efficient Synthesis of Ring B of the Bryostatins
Lu, J., Song, Z., Zhang, Y., Gan, Z., & Li, H. (2012) · Angewandte Chemie · doi:10.1002/ange.201201323 · Cited by 16
Improved and large-scale synthesis of 10-methyl-aplog-1, a potential lead for an anticancer drug
Kikumori, M., Yanagita, R. C., & Irie, K. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.11.026 · Cited by 16

Authors: Kortmansky, J., & Schwartz, G. K.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Kortmansky, Jeremy
Schwartz, Gary K.
Venue: Cancer Investigation
Publisher: Informa UK Limited
Published: 2003-01
Volume: 21
Issue: 6
Pages: 924-936
ISSN: 0735-7907 (ISSN-L)
1532-4192
DOI: 10.1081/cnv-120025095
OpenAlex: W1996339149
Cited by: 183
References: 109
Citations by year: 2026: 5 · 2025: 10 · 2024: 5 · 2023: 2 · 2022: 8 · 2021: 7 · 2020: 8 · 2019: 6 · 2018: 3 · 2017: 12 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 4 · 2012: 12
FWCI: 2.07
Type: journal article
Language: en
Open access: closed
Locations: Cancer Investigation (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA67819, CA09207, R01CA067819, T32CA009207)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords: bryostatin 1, protein kinase C, PKC inhibitors, macrocyclic lactones, marine natural products, cancer therapy, chemosensitization, apoptosis, cell differentiation, hematologic malignancies, solid tumors, drug toxicity, clinical trials
MeSH terms: Antineoplastic Agents, Cell Differentiation, Humans, Lactones, Nausea, Pain, Protein Kinase C, Vomiting, Down-Regulation, Apoptosis, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Macrolides, Bryostatins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks